FASST – A trial targeting fibrosis in the skin
The FASST (For A Systemic Sclerosis Trial) trial is a phase 2 clinical trial sponsored by Inventiva Pharma.The purpose of this study is to evaluate the effectiveness and safety of IVA337 for the treatment of Diffuse Cutaneous Systemic Sclerosis.
IVA337 is a new drug with anti-fibrotic properties meaning that it might be able to act on several components of the fibrotic process and on several organs.
The primary objective of this study is to evaluate in patients suffering from diffuse cutaneous SSc (DcSSc) the effect of 800mg and 1200mg IVA337 daily on the skin compared to placebo. The modified Rodnan Skin Score (mRSS) will be used to determine the changes in skin.
The trial is randomized, double-blind, placebo-controlled, multicentre proof-of-concept trial of IVA337 in the treatment of diffuse cutaneous systemic sclerosis.
Go to www.fassttrial.com for further information.
news & events
We know these are worrying times. We have gathered information to answer your questions and concerns.
Join the webinar on Scleroderma and COVID-19 this Saturday, March 21.
Read about positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Ofev.